Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion-Dependent Patients With Myelodysplastic Syndrome Full Text
Journal of Clinical Oncology, 05/02/2012
List AF et al. – Deferasirox reduces serum ferritin and Labile plasma iron (LPI) in transfusion–dependent patients with MDS. A subset of patients had an improvement in hematologic and hepatic parameters.